Payment overview · 2025
General Payments
$46.52
3 reported records · 2 companies
Healthcare provider profile · identity verified
Drew W. Bright, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITELAND, IN · NPI 1962796649
Verified facts
What the public records show
CMS Open Payments records show Drew W. Bright, MD received $46.52 in general payments during 2025 across 3 reported records.
GlaxoSmithKline, LLC. accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.35 | 65.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.17 | 34.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.52 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 114 |
| Lisinopril | Lisinopril | 319 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 91 |
| Trazodone Hcl | Trazodone Hcl | 305 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 90 |
| Gabapentin | Gabapentin | 300 | 72 |
| Alprazolam | Alprazolam | 241 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 238 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 238 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 64 |
| Losartan Potassium | Losartan Potassium | 215 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 55 |
| Metformin Hcl | Metformin Hcl | 204 | 61 |
| Omeprazole | Omeprazole | 184 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 45 |
| Clonazepam | Clonazepam | 163 | 22 |
| Sertraline Hcl | Sertraline Hcl | 150 | 43 |
| Meloxicam | Meloxicam | 143 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 34 |
| Allopurinol | Allopurinol | 128 | 35 |
| Jardiance | Empagliflozin | 128 | 32 |
| Simvastatin | Simvastatin | 122 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 37 |
| Prednisone | Prednisone | 110 | 53 |
| Ozempic | Semaglutide | 108 | 19 |
| Eliquis | Apixaban | 106 | 23 |
| Furosemide | Furosemide | 106 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 27 |
| Mounjaro | Tirzepatide | 98 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 24 |
| Tramadol Hcl | Tramadol Hcl | 84 | 21 |
| Buspirone Hcl | Buspirone Hcl | 82 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 17 |
| Celecoxib | Celecoxib | 79 | 21 |
| Potassium Chloride | Potassium Chloride | 78 | 25 |
| Glimepiride | Glimepiride | 74 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 17 |
| Torsemide | Torsemide | 66 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 14 |
| Montelukast Sodium | Montelukast Sodium | 64 | 22 |
| Spironolactone | Spironolactone | 63 | 17 |
| Famotidine | Famotidine | 60 | 18 |
| Pregabalin | Pregabalin | 57 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 57 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 55 | 13 |
| Metformin Hcl Er | Metformin Hcl | 55 | 19 |
| Lorazepam | Lorazepam | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 14 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 28 |
| Carvedilol | Carvedilol | 43 | 14 |
| Diazepam | Diazepam | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Valsartan | Valsartan | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Finasteride | Finasteride | 40 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 13 |
| Trulicity | Dulaglutide | 38 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 27 |
| Primidone | Primidone | 35 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 26 |
| Temazepam | Temazepam | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 11 |
| Estradiol | Estradiol | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Azithromycin | Azithromycin | 25 | 23 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Baclofen | Baclofen | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Norgestimate-Ethinyl Estradiol | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.52 · 3 records | GlaxoSmithKline, LLC. | BEXSERO, BodyGuardian, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error